3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Triple Negative Breast Neoplasms
2
Breast Neoplasms, Male
1
Breast Neoplasms
1
Interventions
Cyclophosphamide
5
Trastuzumab
4
Taxes
4
Docetaxel
4
Paclitaxel
3
Albumin-Bound Paclitaxel
3
tipifarnib
2
sargramostim
2
liposomal doxorubicin
2
Vorinostat
2
Immunohistochemistry
2
Granulocyte-Macrophage Colony-Stimulating Factor
2
Filgrastim
2
Enzyme-Linked Immunosorbent Assay
2
Doxorubicin
2
Capecitabine
2
temsirolimus
1
seviteronel
1
romidepsin
1
poly(I).poly(c12,U)
1
pertuzumab
1
pegfilgrastim
1
oblimersen
1
ixabepilone
1
interferon gamma-1b
1
flt3 ligand protein
1
denileukin diftitox
1
cixutumumab
1
alvocidib
1
Vaccines
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Breast Neoplasms, Male
×
seviteronel
×
Clear all
NCT02580448
2019-02-01
CLARITY-01
Innocrin Pharmaceutical
Phase 1/2
Completed
175 enrolled